Sentences with phrase «specific tumor responses»

If researchers can use the mice to gather information about specific tumor responses to specific drugs, then they can bank that information to be used in the general population.

Not exact matches

Scientists now know that what matters most in determining the behavior of a particular cancer (and its response to specific therapy) are the molecular pathways that drive malignant cell growth instead of where the tumor begins in the body.

Their results demonstrate that specific rhoptry and dense granule effector proteins that T. gondii secretes before and after host cell invasion, respectively, control the development of an effective host antitumor response, and increase the survival of mice with ovarian tumors.

He also studies the mechanisms of antigen presentation to T cells, the impact of immunoregulation on tumor antigen - specific responses, and characterization of the tumor - immune microenvironment.

She is investigating the role of glycosylated molecules in tumor progression and metastasis, tissue - and species - specific expression of lectin receptors that play a role in regulating host innate immune responses and inflammation, and the immunological mechanisms underlying chronic inflammation and cancer development.

Dr. Gnjatic's research focuses on human antigen - specific immune responses to tumor antigens, in an attempt to define new targets for the development of cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail.

The response was not specific to tumor type.

However, despite this success, the use of immunotherapy remains limited by the scarcity of tumor - specific antigens — substances that can trigger an immune system response to a particular type of cancer.

The Yale - led study performed whole exome sequencing ¬ — a technique for sequencing all the expressed genes in a genome ¬ — on TNBC tumors to identify mutations in specific genes or pathways that may indicate response or resistance to the standard of care, which is anthracycline / taxane (ACT) chemotherapy.

Most importantly, many of the T cells were able to recognize the tumor cells directly, demonstrating that the vaccine had triggered a tumor - specific immune response that could target the patient's tumor.

«Our results clearly demonstrate a significant, although unexpected, role for specific gut bacteria in enhancing the immune system's response to melanoma and possibly many other tumor types,» said study director Thomas Gajewski, MD, PhD, professor of medicine and pathology at the University of Chicago.

A personal cancer treatment vaccine that targets distinctive «neoantigens» on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana - Farber Cancer Institute and the Broad Institute of MIT and Harvard.

Using transplantable tumor models expressing antigen in an inducible manner or spontaneous tumor models expressing nominal antigens, we try to decipher whether the tumor is ignored or leads to deletion, anergy or class switch of the specific immune response or generate suppressor T cells.

We study tumor specimens and companion normal tissues to determine the molecular features — including DNA mutations, epigenetics, transcriptomics, and proteomics — associated with specific patient responses.

Investigating conventional MHC - restricted T cell responses specific for tumor - associated peptide antigens, and local immune contextures, in mediating cancer control in patients following neoadjuvant (per - surgery) therapy.

Specifically, TheraT ® has proven to be safe in animals as well as capable of eliciting uniquely potent antigen - specific CD8 + cytotoxic T cell responses and strong tumor control in mice.

Using new technologies to analyze thousands of genes and proteins simultaneously from tumors, Dr. Chak hopes to identify molecular patterns that will predict an individual's response to specific agents.

The laboratory of Vincenzo Cerundolo is the first group to report the use of tetrameric soluble class I / peptide complexes (tetramers) for the identification of tumor - specific cytotoxic T lymphocytes (CTLs), and subsequently shows that these novel reagents allow rapid and accurate analysis of human CTL responses.

Cancer vaccines are designed to stimulate an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Through her CLIP Grant, she is analyzing patient samples to determine how Poly ICLC (a TLR agonist) affects the tumor environment and immune responses against specific mutations, to identify how Poly ICLC could complement existing immunotherapies.

The median time to response was 1.8 months, and responses occurred regardless of tumor type, patient age, or specific TRK fusion characteristics.

Therapeutic vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion critumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criTumor type specific exclusion criteria

Therapeutic cancer vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Cancer vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens.

Over the past few years, they have extended their research to understand how products of cellular necrosis and the innate immune responses they induce affect the tumor microenvironment, with a specific focus on ovarian cancer.

Miroslav Machala, head of the Department of Chemistry and Toxicology at the Veterinary Research Institute in the Czech Republic, said in an emailed response that, while these specific compounds lack data, these types of PCBs could potentially promote tumor growth as well.

Identifying tumor - specific biomarkers to optimize selection of targeted therapies and to better predict response to therapy

There, they will be exposed to tumor antigens released from dying glioma cells through TK + valacyclovir - induced glioma cell death, and thus mediate a specific anti-malignant glioma immune response against remaining malignant glioma cells.

I am currently working with Zika virus and how it affects the T cell response and T cell signaling through tumor necrosis receptor (TNFR) signaling components OX40, 4 - 1BB, and CD27 in specific mouse model systems.

If ablating the patient's autologous tumor can stimulate a tumor - specific immune response that persists after the tumor is removed, then creating an ally is what we would be doing.

They do, however, play a key role in helping to boost the anti-tumor immune response by: (1) expanding the number and improving the function of existing CTLs that are specific to the same tumor antigen; and (2) providing help to other immune cells, including B lymphocytes that are precursors to antibodies and natural killer (NK) cells that are also important in the overall anti-tumor immune response.

We believe DCs are the most important immune cells to target because they initiate the specific immune response that generates CTLs to kill the tumor.

When introduced into the bladder, TICE BCG elicits a specific immune response that fights the tumor.